10/051,243

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR







G1 [@1],[@2],[@3]

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sam
SAMPLE SEARCH INITIATED 15:03:44 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 1408 TO ITERATE

71.0% PROCESSED 1000 ITERATIONS 4 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 25909 TO 30411
PROJECTED ANSWERS: 4 TO 254

L2 4 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 15:03:54 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 30238 TO ITERATE

100.0% PROCESSED 30238 ITERATIONS 95 ANSWERS
SEARCH TIME: 00.00.01

L3 95 SEA SSS FUL L1

=>
Uploading C:\Program Files\Stnexp\Queries\10051243h.str

L4 STRUCTURE UPLOADED

=> s l4 sam
SAMPLE SEARCH INITIATED 15:04:55 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 1408 TO ITERATE

71.0% PROCESSED 1000 ITERATIONS 0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 25909 TO 30411
PROJECTED ANSWERS: 0 TO 0

L5 0 SEA SSS SAM L4

=> s l4 full
FULL SEARCH INITIATED 15:05:02 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 30238 TO ITERATE

100.0% PROCESSED 30238 ITERATIONS 12 ANSWERS
SEARCH TIME: 00.00.01

L6 12 SEA SSS FUL L4

=> d l6

L6 ANSWER 1 OF 12 REGISTRY COPYRIGHT 2004 ACS on STN
RN 484040-87-1 REGISTRY
CN 1,2-Naphthalenedione, 2-oxime, lithium salt (9CI) (CA INDEX NAME)
MF C10 H7 N O2 . Li
SR Chemical Library
CRN (6373-60-0)



● Li

=> file caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 313.87 314.08

FILE 'CAPLUS' ENTERED AT 15:05:38 ON 21 DEC 2004

FILE COVERS 1907 - 21 Dec 2004 VOL 141 ISS 26

FILE LAST UPDATED: 20 Dec 2004 (20041220/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d his

(FILE 'HOME' ENTERED AT 15:02:24 ON 21 DEC 2004)

FILE 'REGISTRY' ENTERED AT 15:02:35 ON 21 DEC 2004
L1 STRUCTURE UPLOADED
L2 4 S L1 SAM
L3 95 S L1 FULL
L4 STRUCTURE UPLOADED
L5 0 S L4 SAM
L6 12 S L4 FULL

FILE 'CAPLUS' ENTERED AT 15:05:38 ON 21 DEC 2004

=> s l6
L7 60 L6

=> s l7 and glutamate
93463 GLUTAMATE
1071 GLUTAMATES
93843 GLUTAMATE
(GLUTAMATE OR GLUTAMATES)
L8 2 L7 AND GLUTAMATE

=> d fbib abs hitstr 1-2 l8

L8 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:63831 CAPLUS
DN 134:125960
TI Use of β-naphthoquinone derivatives for making medicines having an inhibiting effect on the release of **glutamate** by the brain
IN Israel, Maurice; Molgo, Jordi; Bloy, Christian; Mattei, Cesar
PA Centre National de la Recherche Scientifique (C.N.R.S.), Fr.
SO PCT Int. Appl., 22 pp.
CODEN: PIXXD2
DT Patent
LA French
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	WO 2001005404	A1	20010125	WO 2000-FR2120		20000721
	W: JP, US					
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE					
				FR 1999-9469	A	19990721
	FR 2796552	A1	20010126	FR 1999-9469		19990721
	EP 1196176	A1	20020417	EP 2000-958596		20000721
	EP 1196176	B1	20040204			
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI					
				FR 1999-9469	A	19990721
				WO 2000-FR2120	W	20000721
	JP 2003504405	T2	20030204	JP 2001-510459		20000721
				FR 1999-9469	A	19990721
				WO 2000-FR2120	W	20000721
	AT 268599	E	20040615	AT 2000-958596		20000721
				FR 1999-9469	A	19990721
				WO 2000-FR2120	W	20000721

PT 1196176	T	20040831	PT 2000-958596		20000721
			FR 1999-9469	A	19990721
ES 2215716	T3	20041016	ES 2000-958596		20000721
			FR 1999-9469	A	19990721
US 2002115617	A1	20020822	US 2002-51243		20020122
			FR 1999-9469	A	19990721
			WO 2000-FR2120	A2	20000721

GI



I II

AB β-Naphthoquinone derivs. are provided for making medicines with an inhibiting effect on the release of **glutamate** by the brain, the derivs. corresponding to I (R = NHCONH2, NHCOCH3, OH) and glucuronide derivs. II and their pharmaceutically acceptable acid addition salts. The invention is applicable to neurol. diseases.

IT **6373-60-0 15687-37-3 51055-26-6**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(β-naphthoquinone derivs. for inhibiting release of **glutamate** in brain)

RN 6373-60-0 CAPLUS
CN 1,2-Naphthalenedione, 2-oxime (9CI) (CA INDEX NAME)



RN 15687-37-3 CAPLUS
CN Hydrazinecarboxamide, 2-(1-oxo-2(1H)-naphthalenylidene)- (9CI) (CA INDEX NAME)



RN 51055-26-6 CAPLUS
CN Acetic acid, (1-oxo-2(1H)-naphthalenylidene)hydrazide (9CI) (CA INDEX

NAME)



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1999:520285 CAPLUS
DN 131:346372
TI Naftazone reduces **glutamate** cerebrospinal fluid levels in rats and **glutamate** release from mouse cerebellum synaptosomes
AU Mattei, C.; Molgo, J.; Joseph, X.; Israe, M.; Bloy, C.
CS Institute of Medical Sciences,Department of Biomedical Sciences, University of Aberdeen, Aberdeen, UK
SO Neuroscience Letters (1999), 271(3), 183-186
CODEN: NELED5; ISSN: 0304-3940
PB Elsevier Science Ireland Ltd.
DT Journal
LA English
AB It is well known that an excessive release of **glutamate** in the mammalian brain plays a major role in several neurol. diseases. Naftazone (Etioven®) is a currently used vasoprotectant drug that is metabolized in humans by reduction and glucuronidation. In the present study naftazone was found to decrease **glutamate** levels in the cerebrospinal fluid (CSF) of rats treated for 15 days, as determined by a chemiluminescent **glutamate** assay reaction. Naftazone and its glucuronide derivative also reduced resp. spontaneous and high K+-evoked **glutamate** release from mouse cerebellum synaptosomes. It is likely that naftazone and its glucuronide metabolite contribute in vivo to decrease **glutamate** levels in the CSF through their inhibitory actions on **glutamate** release.
IT **15687-37-3**, Naftazone
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(naftazone reduces **glutamate** cerebrospinal fluid levels in rats and **glutamate** release from mouse cerebellum synaptosomes)
RN 15687-37-3 CAPLUS
CN Hydrazinecarboxamide, 2-(1-oxo-2(1H)-naphthalenylidene)- (9CI) (CA INDEX NAME)

Used this- they beat the date



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

Uploading C:\Program Files\Stnexp\Queries\10051243s.str

L9 STRUCTURE UPLOADED

=> s l9 full
FULL SEARCH INITIATED 15:09:56 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 97 TO ITERATE

100.0% PROCESSED 97 ITERATIONS 3 ANSWERS
SEARCH TIME: 00.00.01

L10 3 SEA SSS FUL L9

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	156.68	483.42

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-1.40

FILE 'CAPLUS' ENTERED AT 15:10:01 ON 21 DEC 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 21 Dec 2004 VOL 141 ISS 26
FILE LAST UPDATED: 20 Dec 2004 (20041220/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l10
L11 2 L10

=> s l11 and glutamate
93463 GLUTAMATE
1071 GLUTAMATES
93843 GLUTAMATE
(GLUTAMATE OR GLUTAMATES)
L12 2 L11 AND GLUTAMATE

=> d fbib abs hitstr 1-2 l12

L12 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:63831 CAPLUS
DN 134:125960
TI Use of β-naphthoquinone derivatives for making medicines having an inhibiting effect on the release of **glutamate** by the brain
IN Israel, Maurice; Molgo, Jordi; Bloy, Christian; Mattei, Cesar
PA Centre National de la Recherche Scientifique (C.N.R.S.), Fr.

SO PCT Int. Appl., 22 pp.
CODEN: PIXXD2
DT Patent
LA French
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	WO 2001005404	A1	20010125	WO 2000-FR2120		20000721
	W: JP, US					
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE					
				FR 1999-9469	A	19990721
	FR 2796552	A1	20010126	FR 1999-9469		19990721
	EP 1196176	A1	20020417	EP 2000-958596		20000721
	EP 1196176	B1	20040204			
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI					
				FR 1999-9469	A	19990721
				WO 2000-FR2120	W	20000721
	JP 2003504405	T2	20030204	JP 2001-510459		20000721
				FR 1999-9469	A	19990721
				WO 2000-FR2120	W	20000721
	AT 268599	E	20040615	AT 2000-958596		20000721
				FR 1999-9469	A	19990721
				WO 2000-FR2120	W	20000721
	PT 1196176	T	20040831	PT 2000-958596		20000721
				FR 1999-9469	A	19990721
	ES 2215716	T3	20041016	ES 2000-958596		20000721
				FR 1999-9469	A	19990721
	US 2002115617	A1	20020822	US 2002-51243		20020122
				FR 1999-9469	A	19990721
				WO 2000-FR2120	A2	20000721

GI



AB β-Naphthoquinone derivs. are provided for making medicines with an inhibiting effect on the release of **glutamate** by the brain, the derivs. corresponding to I (R = NHCONH2, NHCOCH3, OH) and glucuronide derivs. II and their pharmaceutically acceptable acid addition salts. The invention is applicable to neurol. diseases.

IT **250585-74-1 321546-47-8 321546-48-9**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(β-naphthoquinone derivs. for inhibiting release of **glutamate** in brain)

RN 250585-74-1 CAPLUS

CN β-D-Glucopyranosiduronic acid, 2-[(aminocarbonyl)hydrazono]-1,2-

dihydro-1-naphthalenyl (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 321546-47-8 CAPLUS
CN β-D-Glucopyranosiduronic acid, 2-(acetylhydrazono)-1,2-dihydro-1-naphthalenyl (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 321546-48-9 CAPLUS
CN β-D-Glucopyranosiduronic acid, 1,2-dihydro-2-(hydroxyimino)-1-naphthalenyl (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1999:520285 CAPLUS
DN 131:346372
TI Naftazone reduces **glutamate** cerebrospinal fluid levels in rats and **glutamate** release from mouse cerebellum synaptosomes
AU Mattei, C.; Molgo, J.; Joseph, X.; Israe, M.; Bloy, C.
CS Institute of Medical Sciences,Department of Biomedical Sciences, University of Aberdeen, Aberdeen, UK
SO Neuroscience Letters (1999), 271(3), 183-186
CODEN: NELED5; ISSN: 0304-3940
PB Elsevier Science Ireland Ltd.
DT Journal
LA English
AB It is well known that an excessive release of **glutamate** in the mammalian brain plays a major role in several neurol. diseases. Naftazone (Etioven®) is a currently used vasoprotectant drug that is metabolized in humans by reduction and glucuronidation. In the present study naftazone was found to decrease **glutamate** levels in the cerebrospinal fluid (CSF) of rats treated for 15 days, as determined by a chemiluminescent **glutamate** assay reaction. Naftazone and its glucuronide derivative also reduced resp. spontaneous and high K+-evoked **glutamate** release from mouse cerebellum synaptosomes. It is likely that naftazone and its glucuronide metabolite contribute in vivo to decrease **glutamate** levels in the CSF through their inhibitory actions on **glutamate** release.
IT **250585-74-1**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(naftazone reduces **glutamate** cerebrospinal fluid levels in rats and **glutamate** release from mouse cerebellum synaptosomes)
RN 250585-74-1 CAPLUS
CN β-D-Glucopyranosiduronic acid, 2-[(aminocarbonyl)hydrazono]-1,2-dihydro-1-naphthalenyl (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT